Shanghai's biopharmaceutical industry, one of the city's three leading sectors, is receiving stronger intellectual property support as the Shanghai Intellectual Property Administration (SIPA) implements reforms in multiple areas. The reforms focus on enhancing services, refining governance tools, and boosting innovation capabilities for enterprises.
A key priority is enhancing administrative adjudication to better protect patented achievements in pharmaceuticals and medical devices. In recent years, the city has handled a series of influential adjudication cases, many of which were selected as national and municipal models for IP protection.
Shanghai's approaches in the biopharmaceutical field have also been recognized in business-environment innovation programs, underscoring its growing role as a benchmark for high-standard IP governance.
Shanghai is further advancing patent-navigation projects to support industrial planning and guide technology development. Initiatives now cover areas such as nucleic-acid medicines and precision-medicine clusters, enabling enterprises and localities to optimize research directions and strengthen long-term development strategies through evidence-based analysis.
The city also encourages universities, research institutes, and medical institutions to cultivate high-value patents and improve commercialization performance. Dedicated IP operation centers within the healthcare system help raise patent quality, strengthen training, and streamline the transformation of scientific achievements.
Together, these efforts reinforce a full innovation chain — linking creation, protection, and application — and enhance Shanghai's capacity to grow new quality productive forces and expand its global influence in life-science innovation.
